Bristol's Opdivo-Yervoy duo snares a quick FDA nod in first-line kidney cancer
admin 16th April 2018 Uncategorised 0After an early setback for Bristol-Myers Squibb’s Opdivo-Yervoy combo in first-line kidney cancer—when the duo failed to stave off kidney cancer progression better than Pfizer’s Sutent did—the combo pressed on to show it could help patients live longer. And now, the New Jersey drugmaker has the kidney cancer go-ahead it’s been chasing.
More: Bristol's Opdivo-Yervoy duo snares a quick FDA nod in first-line kidney cancer
Source: fierce